Corrigendum to “Silencing Adenosine A2a Receptor Enhances Dendritic Cell-Based Cancer Immunotherapy” [Nanomedicine Nanotechnol Biol Med 29 (2020) 102240] (Nanomedicine: Nanotechnology, Biology, and Medicine (2020) 29, (S1549963420300940), (10.1016/J.Nano.2020.102240))

Corrigendum to “Silencing Adenosine A2a Receptor Enhances Dendritic Cell-Based Cancer Immunotherapy” [Nanomedicine Nanotechnol Biol Med 29 (2020) 102240] (Nanomedicine: Nanotechnology, Biology, and Medicine (2020) 29, (S1549963420300940), (10.1016/J.Nano.2020.102240)) Publisher Pubmed

Masjedi A^{1, 2} ; Ahmadi A³ ; Ghanee S¹ ; Malakotikhah F⁴ ; Afjadi MN⁵ ; Irandoust M⁶ ; Kiani FK⁶ ; Asl SH⁶ ; Atyabi F⁷ ; Hassannia H⁸ ; Hojjatfarsangi M^{9, 10} ; Namdar A¹¹ ; Ghalamfarsa G¹² ; Jadidiniaragh F^{1, 13}

Show Affiliations

1. Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
2. Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran
3. Department of Chemical and Materials Engineering, The University of Alabama in Huntsville, AL, United States
4. Department of Clinical Biochemistry, Islamic Azad University, Falavarjan Branch, Isfahan, Iran
5. Department of Biochemistry, Faculty of Biological Sciences, University of Tarbiat Modares, Tehran, Iran
6. Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
7. Nanotechnology Research Centre, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
8. Immunogenetic Research Center, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran
9. Bioclinicum, Department of Oncology-Pathology, Karolinska Institute, Stockholm, Sweden
10. The Persian Gulf Marine Biotechnology Medicine Research Center, Bushehr University of Medical Sciences, Bushehr, Iran
11. Department of Oncology, Cross Cancer Institute, The University of Alberta, Edmonton, AB, Canada
12. Cellular and Molecular Research Center, Yasuj University of Medical Sciences, Yasuj, Iran
13. Department of Immunology, School of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran

Source: Nanomedicine: Nanotechnology# Biology# and Medicine Published:2023

Abstract

The authors regret that the name of Sepideh Ghanee and his affiliation was incorrect in the published article. It has been corrected now. The authors would like to apologise for any inconvenience caused. © 2023 Elsevier Inc.

Style	Citing Format
MLA	Masjedi A, et al.. "Corrigendum to “Silencing Adenosine A2a Receptor Enhances Dendritic Cell-Based Cancer Immunotherapy” [Nanomedicine Nanotechnol Biol Med 29 (2020) 102240] (Nanomedicine: Nanotechnology, Biology, and Medicine (2020) 29, (S1549963420300940), (10.1016/J.Nano.2020.102240))." Nanomedicine: Nanotechnology# Biology# and Medicine, vol. 51, no. , 2023, pp. -.
APA	Masjedi A, Ahmadi A, Ghanee S, Malakotikhah F, Afjadi MN, Irandoust M, Kiani FK, Asl SH, Atyabi F, Hassannia H, Hojjatfarsangi M, Namdar A, Ghalamfarsa G, Jadidiniaragh F (2023). Corrigendum to “Silencing Adenosine A2a Receptor Enhances Dendritic Cell-Based Cancer Immunotherapy” [Nanomedicine Nanotechnol Biol Med 29 (2020) 102240] (Nanomedicine: Nanotechnology, Biology, and Medicine (2020) 29, (S1549963420300940), (10.1016/J.Nano.2020.102240)). Nanomedicine: Nanotechnology# Biology# and Medicine, 51(), -.
Chicago	Masjedi A, Ahmadi A, Ghanee S, Malakotikhah F, Afjadi MN, Irandoust M, Kiani FK, et al.. "Corrigendum to “Silencing Adenosine A2a Receptor Enhances Dendritic Cell-Based Cancer Immunotherapy” [Nanomedicine Nanotechnol Biol Med 29 (2020) 102240] (Nanomedicine: Nanotechnology, Biology, and Medicine (2020) 29, (S1549963420300940), (10.1016/J.Nano.2020.102240))." Nanomedicine: Nanotechnology# Biology# and Medicine 51, no. (2023): -.
Harvard	Masjedi A et al. (2023) 'Corrigendum to “Silencing Adenosine A2a Receptor Enhances Dendritic Cell-Based Cancer Immunotherapy” [Nanomedicine Nanotechnol Biol Med 29 (2020) 102240] (Nanomedicine: Nanotechnology, Biology, and Medicine (2020) 29, (S1549963420300940), (10.1016/J.Nano.2020.102240))', Nanomedicine: Nanotechnology# Biology# and Medicine, 51(), pp. -.
Vancouver	Masjedi A, Ahmadi A, Ghanee S, Malakotikhah F, Afjadi MN, Irandoust M, et al.. Corrigendum to “Silencing Adenosine A2a Receptor Enhances Dendritic Cell-Based Cancer Immunotherapy” [Nanomedicine Nanotechnol Biol Med 29 (2020) 102240] (Nanomedicine: Nanotechnology, Biology, and Medicine (2020) 29, (S1549963420300940), (10.1016/J.Nano.2020.102240)). Nanomedicine: Nanotechnology# Biology# and Medicine. 2023;51():-.
BibTex	@article{ author = {Masjedi A and Ahmadi A and Ghanee S and Malakotikhah F and Afjadi MN and Irandoust M and Kiani FK and Asl SH and Atyabi F and Hassannia H and Hojjatfarsangi M and Namdar A and Ghalamfarsa G and Jadidiniaragh F}, title = {Corrigendum to “Silencing Adenosine A2a Receptor Enhances Dendritic Cell-Based Cancer Immunotherapy” [Nanomedicine Nanotechnol Biol Med 29 (2020) 102240] (Nanomedicine: Nanotechnology, Biology, and Medicine (2020) 29, (S1549963420300940), (10.1016/J.Nano.2020.102240))}, journal = {Nanomedicine: Nanotechnology# Biology# and Medicine}, volume = {51}, number = {}, pages = {-}, year = {2023} }
RIS	TY - JOUR AU - Masjedi A AU - Ahmadi A AU - Ghanee S AU - Malakotikhah F AU - Afjadi MN AU - Irandoust M AU - Kiani FK AU - Asl SH AU - Atyabi F AU - Hassannia H AU - Hojjatfarsangi M AU - Namdar A AU - Ghalamfarsa G AU - Jadidiniaragh F TI - Corrigendum to “Silencing Adenosine A2a Receptor Enhances Dendritic Cell-Based Cancer Immunotherapy” [Nanomedicine Nanotechnol Biol Med 29 (2020) 102240] (Nanomedicine: Nanotechnology, Biology, and Medicine (2020) 29, (S1549963420300940), (10.1016/J.Nano.2020.102240)) JO - Nanomedicine: Nanotechnology# Biology# and Medicine VL - 51 IS - SP - EP - PY - 2023 ER -

Style

Citing Format

MLA

Masjedi A, et al.. "Corrigendum to “Silencing Adenosine A2a Receptor Enhances Dendritic Cell-Based Cancer Immunotherapy” [Nanomedicine Nanotechnol Biol Med 29 (2020) 102240] (Nanomedicine: Nanotechnology, Biology, and Medicine (2020) 29, (S1549963420300940), (10.1016/J.Nano.2020.102240))." Nanomedicine: Nanotechnology# Biology# and Medicine, vol. 51, no. , 2023, pp. -.

APA

Masjedi A, Ahmadi A, Ghanee S, Malakotikhah F, Afjadi MN, Irandoust M, Kiani FK, Asl SH, Atyabi F, Hassannia H, Hojjatfarsangi M, Namdar A, Ghalamfarsa G, Jadidiniaragh F (2023). Corrigendum to “Silencing Adenosine A2a Receptor Enhances Dendritic Cell-Based Cancer Immunotherapy” [Nanomedicine Nanotechnol Biol Med 29 (2020) 102240] (Nanomedicine: Nanotechnology, Biology, and Medicine (2020) 29, (S1549963420300940), (10.1016/J.Nano.2020.102240)). Nanomedicine: Nanotechnology# Biology# and Medicine, 51(), -.

Chicago

Masjedi A, Ahmadi A, Ghanee S, Malakotikhah F, Afjadi MN, Irandoust M, Kiani FK, et al.. "Corrigendum to “Silencing Adenosine A2a Receptor Enhances Dendritic Cell-Based Cancer Immunotherapy” [Nanomedicine Nanotechnol Biol Med 29 (2020) 102240] (Nanomedicine: Nanotechnology, Biology, and Medicine (2020) 29, (S1549963420300940), (10.1016/J.Nano.2020.102240))." Nanomedicine: Nanotechnology# Biology# and Medicine 51, no. (2023): -.

Harvard

Masjedi A et al. (2023) 'Corrigendum to “Silencing Adenosine A2a Receptor Enhances Dendritic Cell-Based Cancer Immunotherapy” [Nanomedicine Nanotechnol Biol Med 29 (2020) 102240] (Nanomedicine: Nanotechnology, Biology, and Medicine (2020) 29, (S1549963420300940), (10.1016/J.Nano.2020.102240))', Nanomedicine: Nanotechnology# Biology# and Medicine, 51(), pp. -.

Vancouver

Masjedi A, Ahmadi A, Ghanee S, Malakotikhah F, Afjadi MN, Irandoust M, et al.. Corrigendum to “Silencing Adenosine A2a Receptor Enhances Dendritic Cell-Based Cancer Immunotherapy” [Nanomedicine Nanotechnol Biol Med 29 (2020) 102240] (Nanomedicine: Nanotechnology, Biology, and Medicine (2020) 29, (S1549963420300940), (10.1016/J.Nano.2020.102240)). Nanomedicine: Nanotechnology# Biology# and Medicine. 2023;51():-.

BibTex

@article{ author = {Masjedi A and Ahmadi A and Ghanee S and Malakotikhah F and Afjadi MN and Irandoust M and Kiani FK and Asl SH and Atyabi F and Hassannia H and Hojjatfarsangi M and Namdar A and Ghalamfarsa G and Jadidiniaragh F}, title = {Corrigendum to “Silencing Adenosine A2a Receptor Enhances Dendritic Cell-Based Cancer Immunotherapy” [Nanomedicine Nanotechnol Biol Med 29 (2020) 102240] (Nanomedicine: Nanotechnology, Biology, and Medicine (2020) 29, (S1549963420300940), (10.1016/J.Nano.2020.102240))}, journal = {Nanomedicine: Nanotechnology# Biology# and Medicine}, volume = {51}, number = {}, pages = {-}, year = {2023} }

RIS

TY - JOUR
AU - Masjedi A
AU - Ahmadi A
AU - Ghanee S
AU - Malakotikhah F
AU - Afjadi MN
AU - Irandoust M
AU - Kiani FK
AU - Asl SH
AU - Atyabi F
AU - Hassannia H
AU - Hojjatfarsangi M
AU - Namdar A
AU - Ghalamfarsa G
AU - Jadidiniaragh F
TI - Corrigendum to “Silencing Adenosine A2a Receptor Enhances Dendritic Cell-Based Cancer Immunotherapy” [Nanomedicine Nanotechnol Biol Med 29 (2020) 102240] (Nanomedicine: Nanotechnology, Biology, and Medicine (2020) 29, (S1549963420300940), (10.1016/J.Nano.2020.102240))
JO - Nanomedicine: Nanotechnology# Biology# and Medicine
VL - 51
IS -
SP -
EP -
PY - 2023
ER -

Science Communicator Platform

Authors

Authors Affiliations

Abstract